Skip to Main Content

Paper Details

Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.
Oncotarget
24
2016
AKT, ERK1/2, NOTCH, NOTCH-dependent and independent T-ALL cell lines, OP449, PP2A, PP2A catalytic subunit, SET, SET oncoprotein, T, T-, T-ALL, T-ALL cell lines, T-ALL cells, T-cell acute lymphoblastic leukemia, c-MYC, cancers, dovitinib, healthy T cells, human, normal and malignant cells, p70S6 kinase, protein phosphatase 2A, receptor tyrosine kinase, serine, serine/threonine phosphatases, threonine, tumor, tyrosine, tyrosine kinases, tyrosine kinome
Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Cell Line, Tumor, Cell Survival, Child, DNA-Binding Proteins, Enzyme Inhibitors, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Histone Chaperones, Humans, Jurkat Cells, Male, Peptides, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Protein Phosphatase 2, Protein-Tyrosine Kinases, Quinolones, Transcription Factors, Young Adult
Author NameAffiliation
Nameeta P RichardRandall Children's Hospital at Legacy Emanuel
Nameeta P RichardOregon Health and Science University
Raffaella PippaCenter for Applied Medical Research (CIMA), University of Navarra
Megan M ClearyOregon Health and Science University
Megan M ClearyKnight Cancer Institute, Oregon Health and Science University
Alka PuriOregon Health and Science University
Alka PuriKnight Cancer Institute, Oregon Health and Science University
Deanne TibbittsOregon Health and Science University
Shawn MahmoodOregon Health and Science University
Shawn MahmoodKnight Cancer Institute, Oregon Health and Science University
Dale J ChristensenOncotide Pharmaceuticals
Dale J Christensen
Sophia JengDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University
Sophia JengKnight Cancer Institute, Oregon Health and Science University
Shannon K McWeeneyDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University
Shannon K McWeeneyKnight Cancer Institute, Oregon Health and Science University
Alex LookDana-Farber Cancer Institute, Harvard Cancer Center
Bill H ChangOregon Health and Science University
Bill H ChangKnight Cancer Institute, Oregon Health and Science University
Jeffrey W TynerOregon Health and Science University
Jeffrey W TynerKnight Cancer Institute, Oregon Health and Science University
Michael P VitekOncotide Pharmaceuticals
Mar??a D OderoCenter for Applied Medical Research (CIMA), University of Navarra
Rosalie C SearsOregon Health and Science University
Rosalie C SearsKnight Cancer Institute, Oregon Health and Science University
Rosalie C SearsOregon Health and Science University
Rosalie C SearsKnight Cancer Institute, Oregon Health and Science University
Anupriya AgarwalOregon Health and Science University
Anupriya AgarwalOregon Health and Science University
Anupriya AgarwalKnight Cancer Institute, Oregon Health and Science University
  • 1 - 30

Datasets

Release 1.2